Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引：1

作者：

Galsky, Matthew D.

Daneshmand, Siamak

Izadmehr, Sudeh

Gonzalez-Kozlova, Edgar

Chan, Kevin G.

Lewis, Sara

Achkar, Bassam El

Dorff, Tanya B.

Cetnar, Jeremy Paul

Neil, Brock O.

D'Souza, Anishka

Mamtani, Ronac

Kyriakopoulos, Christos

Jun, Tomi

Gogerly-Moragoda, Mahalya

Brody, Rachel

Xie, Hui

Nie, Kai

Kelly, Geoffrey

Horowitz, Amir

Kinoshita, Yayoi

Ellis, Ethan

Nose, Yohei

Ioannou, Giorgio

Cabal, Rafael

Del Valle, Diane M.

Haines, G. Kenneth

Wang, Li

Mouw, Kent W.

Samstein, Robert M.

Mehrazin, Reza

Bhardwaj, Nina

Yu, Menggang

Zhao, Qianqian

Kim-Schulze, Seunghee

Sebra, Robert

Zhu, Jun

Gnjatic, Sacha

Sfakianos, John

Pal, Sumanta K.

机构：

[1] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[2] Tisch Cancer Institute,Department of Urology

[3] Icahn School of Medicine at Mount Sinai,Department of Oncological Sciences

[4] Keck School of Medicine of USC,Department of Urology

[5] Norris Comprehensive Cancer Center,Department of Radiology

[6] Tisch Cancer Institute,Department of Medical Oncology & Therapeutics

[7] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[8] City of Hope Comprehensive Cancer Center,Department of Urology

[9] Tisch Cancer Institute,Division of Hematology and Medical Oncology

[10] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[11] City of Hope Comprehensive Cancer Center,Division of Hematology and Medical Oncology

[12] Oregon Health and Science University,Department of Pathology

[13] University of Utah,Department of Genetics and Genomic Sciences

[14] Keck School of Medicine of USC,Department of Pathology, Molecular and Cell

[15] Norris Comprehensive Cancer Center,based Medicine

[16] University of Pennsylvania Abramson Cancer Center,Department of Radiation Oncology

[17] University of Wisconsin Carbone Cancer Center,Department of Radiation Oncology

[18] Genentech,Department of Urology

[19] Tisch Cancer Institute,Department of Biostatistics and Medical Informatics

[20] Icahn School of Medicine at Mount Sinai,undefined

[21] Human Immune Monitoring Center,undefined

[22] Icahn School of Medicine at Mount Sinai,undefined

[23] Precision Immunology Institute,undefined

[24] Icahn School of Medicine at Mount Sinai,undefined

[25] Icahn School of Medicine at Mount Sinai,undefined

[26] Icahn Institute for Data Science and Genomic Technology,undefined

[27] Icahn School of Medicine at Mount Sinai,undefined

[28] Icahn School of Medicine at Mount Sinai,undefined

[29] Gene Dx,undefined

[30] Dana-Farber Cancer Institute/Brigham & Women’s Hospital,undefined

[31] Harvard Medical School,undefined

[32] Tisch Cancer Institute,undefined

[33] Icahn School of Medicine at Mount Sinai,undefined

[34] Tisch Cancer Institute,undefined

[35] Icahn School of Medicine at Mount Sinai,undefined

[36] University of Wisconsin Carbone Cancer Center,undefined

[37] Formerly with the Icahn School of Medicine at Mount Sinai,undefined

来源：

NATURE MEDICINE | 2024年 / 30卷 / 4期

关键词：

D O I：

10.1038/s41591-024-02814-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1211 / 1211

页数：1

共 50 条

[21] Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial
Anari, Fern
O'Neill, John
Choi, Woonyoung
Chen, David Y. T.
Haseebuddin, Mohammed
Kutikov, Alexander
Dulaimi, Essel
Alpaugh, R. Katherine
Devarajan, Karthik
Greenberg, Richard E.
Bilusic, Marijo
Wong, Yu-Ning
Viterbo, Rosalia
Hoffman-Censitsc, Jean H.
Lallas, Costas D.
Trabulsic, Edouard J.
Smaldone, Marc
Geynisman, Daniel M.
Zibelman, Matthew
Lin, Jianqing
Kelly, W. Kevin
Uzzo, Robert
McConkey, David
Plimack, Elizabeth R.
EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (01): : 54 - 60
[22] Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Xing, N.
Han, S.
Jiang, J.
Xu, W.
Shi, B.
Ping, H.
Ji, Z.
Ma, Q.
Wang, H.
Chen, S.
Wang, W.
Fan, X.
Zhou, Q.
Zhang, W.
ANNALS OF ONCOLOGY, 2021, 32 : S714 - S714
[23] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
Yafi, Faysal A.
Kassouf, Wassim
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
[24] Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials
Arcangeli, G.
Strigari, L.
Arcangeli, S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 387 - 396
[25] Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Iyer, Gopa
Balar, Arjun V.
Milowsky, Matthew I.
Bochner, Bernard H.
Dalbagni, Guido
Donat, S. Machele
Herr, Harry W.
Huang, William C.
Taneja, Samir S.
Woods, Michael
Ostrovnaya, Irina
Al-Ahmadie, Hikmat
Arcila, Maria E.
Riches, Jamie C.
Meier, Andreas
Bourque, Caitlin
Shady, Maha
Won, Helen
Rose, Tracy L.
Kim, William Y.
Kania, Brooke E.
Boyd, Mariel E.
Cipolla, Catharine K.
Regazzi, Ashley M.
Delbeau, Daniela
McCoy, Asia S.
Vargas, Hebert Alberto
Berger, Michael F.
Solit, David B.
Rosenberg, Jonathan E.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1949 - +
[26] Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
Matsubara, Nobuaki
Mukai, Hirofumi
Naito, Yoichi
Nezu, Masahiko
Itoh, Kuniaki
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 310 - 317
[27] Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
Li, Kaiwen
Zhong, Wenlong
Fan, Jinhai
Wang, Shaogang
Yu, Dexin
Xu, Tao
Lyu, Jiaju
Wu, Shaoxu
Qin, Tao
Wu, Zhuo
Xu, Longhao
Wu, Kaijie
Liu, Zheng
Hu, Zhiquan
Li, Fan
Wang, Jinyou
Wang, Qi
Min, Jie
Zhang, Zhiqiang
Yu, Luping
Ding, Sentai
Huang, Longfei
Zhao, Tingting
Huang, Jian
Lin, Tianxin
NATURE CANCER, 2024, : 1465 - 1478
[28] Organ-sparing Chemoradiotherapy: a viable Alternative to initial Cystectomy for patients with Muscle-invasive bladder cancer compared to Radiotherpay
Weiss, C.
Sauer, R.
STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 713 - 716
[29] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer
Chang, Sam S.
JOURNAL OF UROLOGY, 2020, 203 (04): : 659 - 660
[30] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer
Voskuilen, Charlotte S.
van der Heijden, Michiel S.
van Rhijn, Basw. G.
EUROPEAN UROLOGY, 2019, 76 (06) : 870 - 871

← 1 2 3 4 5 →